IP Library Granted Patent US 7,696,244
Granted Patent B2
US 7,696,244 · App. 10/556,195 · Granted Apr 13, 2010

Compounds having activity in increasing ion transport by mutant-CFTR and uses thereof

Assignee: The Regents of the University of California
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,696,244
App. No.
10/556,195
Granted
Apr 13, 2010
Kind
B2
Abstract

The invention provides compositions, including pharmaceutical preparations, which comprise one or more substituted thiophene, benzofuran, pyrimidinetrione, dihydropyridine, tetrahydrocarbazol or anthraquinone compounds. The invention also features methods of use of such compositions in increasing activity of mutant-cystic fibrosis transmembrane conductance regulator protein in a cell, e.g. by increasing ion transport in a mutant-CFTR.

Claims (34)

1. A method of increasing halide ion permeability of a cell producing a ΔF508-CFTR protein, said method comprising contacting said cell with a substituted thiophene compound in an amount effective to increase ion permeability of said cell,

wherein said compound has the formula:

wherein n is 1 or 2, and R 1 is a phenyl group substituted with one to two substituents selected from halogen, methyl, amino, and nitro.

2. The method of claim 1 , wherein said ion is a chloride ion or an iodide ion.

3. The method of claim 2 , wherein said ΔF508-CFTR protein is present at a plasma membrane of said cell.

4. The method of claim 1 , wherein said cell contains a recombinant expression cassette that encodes said ΔF508 CFTR protein.

5. The method of claim 1 , wherein said cell contains a genome that encodes said ΔF508-CFTR protein.

6. The method of claim 1 , wherein said compound increases ion transporting activity of said ΔF508-CFTR protein.

7. The method of claim 6 , wherein said ion transporting activity increases a rate of transport of ions across a plasma membrane of said cell.

8. The method of claim 1 , wherein the compound is together with at least one of a pharmaceutically acceptable carrier, a pharmaceutically acceptable diluent, a pharmaceutically acceptable excipient and a pharmaceutically acceptable adjuvant.

9. The method of claim 1 , wherein R 1 has molecular weight of 58-165 Da.

10. The method of claim 8 , wherein the compound is provided in a composition that does not contain detectable dimethyl sulfoxide.

11. The method of claim 1 , wherein the compound is 2-(2-Chloro-benzoylamino)-4,5,6,7-tetrahydro-benzo thiophene-3-carboxylic acid amide or a pharmaceutically acceptable salt thereof.

12. The method of claim 1 , wherein the phenyl group is substituted with halogen.

13. The method of claim 1 , wherein the phenyl group is substituted with methyl.

14. The method of claim 1 , wherein the phenyl group is substituted with amino.

15. The method of claim 1 , wherein the phenyl group is substituted with nitro.

16. A method of increasing chloride ion permeability of a cell producing a ΔF508-CFTR protein, said method comprising

contacting said cell with a substituted thiophene compound in an amount effective to increase ion permeability of said cell,

wherein said compound has the formula:

wherein n is 1 or 2, and R 1 is a phenyl group substituted with one to two substituents selected from halogen, methyl, amino, and nitro;

wherein said contacting is effective in increasing chloride ion permeability of the cell.

17. The method of claim 16 , wherein said ΔF508-CFTR protein is present at a plasma membrane of said cell.

18. The method of claim 16 , wherein said cell contains a recombinant expression cassette that encodes said ΔF508 CFTR protein.

19. The method of claim 16 , wherein said cell contains a genome that encodes said ΔF508-CFTR protein.

20. The method of claim 16 , wherein said compound increases ion transporting activity of said ΔF508-CFTR protein.

21. The method of claim 16 , wherein the compound is together with at least one of a pharmaceutically acceptable carrier, a pharmaceutically acceptable diluent, a pharmaceutically acceptable excipient and a pharmaceutically acceptable adjuvant.

22. The method of claim 21 , wherein the compound is provided in a composition that does not contain detectable dimethyl sulfoxide.

23. The method of claim 16 , wherein R 1 has molecular weight of 58-165 Da.

24. The method of claim 16 , wherein the compound is 2-(2-Chloro-benzoylamino)-4,5,6,7-tetrahydro-benzo thiophene-3-carboxylic acid amide or a pharmaceutically acceptable salt thereof.

25. The method of claim 16 , wherein the phenyl group is substituted with halogen.

26. The method of claim 16 , wherein the phenyl group is substituted with methyl.

27. The method of claim 16 , wherein the phenyl group is substituted with amino.

28. The method of claim 16 , wherein the phenyl group is substituted with nitro.

Assignments (2)
CONFIRMATORY LICENSE Recorded Aug 25, 2010
From: UNIVERSITY OF CALIFORNIA SAN FRANCISCO
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 024879/0462 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 20, 2007
From: VERKMAN, ALAN; GALIETTA, LUIS J.V.; GUY, R. KIPLIN
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 019038/0216 →
Continuity (2)
Provisional Application 6047106000 · May 16, 2003
Related Publication 20070265316A1 · Nov 15, 2007